Adalimumab Dose Reduction and Withdrawal in Stable Non-Infectious Pediatric Uveitis: An Open-Label, Prospective, Pilot Study

CONCLUSIONS: In PNIU children who reached remission for 6 months, ADA dose reduction and withdrawal were associated with a high risk of inflammation recurrence. Timely adjustment of ADA to the last effective dosage frequency can regain control of the inflammation. Detection of ADA serum levels in patients with recurrence may help find the appropriate interval of ADA use.PMID:38652891 | DOI:10.1080/09273948.2024.2343084

Source: Ocular Immunology and Inflammation - April 23, 2024 Category: Allergy & Immunology Authors: P D Yuan Y W Hu X Q Chen G Y Chen Y Pan H Y Lao D Liang Source Type: research